Management of Arrhythmias After Heart Transplant: Current State and Considerations for Future Research

Orthotropic heart transplantation remains the most effective therapy for patients with end-stage heart failure, with a median survival of ≈13 years. Yet, a number of complications are observed after orthotropic heart transplantation, including atrial and ventricular arrhythmias. Several factors cont...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation. Arrhythmia and electrophysiology 2021-03, Vol.14 (3), p.e007954-e007954
Hauptverfasser: Joglar, Jose A., Wan, Elaine Y., Chung, Mina K., Gutierrez, Alejandra, Slaughter, Mark S., Bateson, Brian P., Loguidice, Michael, Drazner, Mark, Kistler, Peter M., Saour, Basil, Poole, Jeanne E., Murtaza, Ghulam, Turagam, Mohit K., Vader, Justin, Lakkireddy, Dhanunjaya, Birati, Edo Y., Dhingra, Ravi, Gopinathannair, Rakesh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e007954
container_issue 3
container_start_page e007954
container_title Circulation. Arrhythmia and electrophysiology
container_volume 14
creator Joglar, Jose A.
Wan, Elaine Y.
Chung, Mina K.
Gutierrez, Alejandra
Slaughter, Mark S.
Bateson, Brian P.
Loguidice, Michael
Drazner, Mark
Kistler, Peter M.
Saour, Basil
Poole, Jeanne E.
Murtaza, Ghulam
Turagam, Mohit K.
Vader, Justin
Lakkireddy, Dhanunjaya
Birati, Edo Y.
Dhingra, Ravi
Gopinathannair, Rakesh
description Orthotropic heart transplantation remains the most effective therapy for patients with end-stage heart failure, with a median survival of ≈13 years. Yet, a number of complications are observed after orthotropic heart transplantation, including atrial and ventricular arrhythmias. Several factors contribute to arrhythmias, such as autonomic denervation, effect of the surgical technique, acute and chronic rejection, and transplant vasculopathy among others. To minimize risk of future arrhythmias, the bicaval technique and minimizing ischemic time are current surgical standards. Sinus node dysfunction is the most common indication for early (within 30 days) pacemaker implantation, whereas atrioventricular block incidence increases as time from transplant increases. Atrial fibrillation can occur in the first few weeks following transplantation but is uncommon in the long term unless secondary to a precipitant such as acute rejection. The most common atrial arrhythmias are atrial flutters, which are mainly typical, but atypical circuits can be observed such as those that involve the remnant donor atrium in regions immediately adjacent to the atrioatrial anastomosis suture line. Choosing the appropriate pharmacological therapy requires careful consideration due to the potential interaction with immunosuppressive agents. Despite historical concerns, adenosine is effective and safe at reduced doses if administered under cardiac monitoring. Catheter ablation has emerged as an effective treatment strategy for symptomatic supraventricular tachycardias, including ablation of atypical flutter circuits. Cardiac allograft vasculopathy is an important risk factor for sudden cardiac death, yet the role of prophylactic implantable cardioverter-defibrillator implant for sudden death prevention is unclear. Current indications for implantable cardioverter-defibrillator implantation are as in the nontransplant population. A number of questions for future research are posed.
doi_str_mv 10.1161/CIRCEP.120.007954
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1161_CIRCEP_120_007954</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33685207</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3465-d77e5a783fefab569d52a4f8039c32a71a91fb311ed1ab1c25f1971bfd5e0c653</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRS0Eorw-gA3yD6TMxHEe7KqIl1QEgrKOJsmYFNKksh0h_p5UAcRidO_inlkcIc4R5ogxXub3z_n10xxDmAMkmY72xBFmEQYK0mj_X5-JY-feAWJMMT4UM6XiVIeQHAnzQB298YY7L3sjF9Y2X77ZrMnJhfFs5R2T9XJlqXPbljp_JfPB2t38xZNnSV0t875z65ot-fXYpOmtvBn8YFk-sxv5qjkVB4Zax2c_eSJeb65X-V2wfLy9zxfLoFJRrIM6SVhTkirDhkodZ7UOKTIpqKxSISVIGZpSIXKNVGIVaoNZgqWpNUMVa3UicPpb2d45y6bY2vWG7FeBUOycFZOzYnRWTM5G5mJitkO54fqP-JU0DqJp8Nm3oxL30Q6fbIuGqfVNAahUEmUqCCFEUAAQjIdafQN22ni4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Management of Arrhythmias After Heart Transplant: Current State and Considerations for Future Research</title><source>MEDLINE</source><source>American Heart Association</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Joglar, Jose A. ; Wan, Elaine Y. ; Chung, Mina K. ; Gutierrez, Alejandra ; Slaughter, Mark S. ; Bateson, Brian P. ; Loguidice, Michael ; Drazner, Mark ; Kistler, Peter M. ; Saour, Basil ; Poole, Jeanne E. ; Murtaza, Ghulam ; Turagam, Mohit K. ; Vader, Justin ; Lakkireddy, Dhanunjaya ; Birati, Edo Y. ; Dhingra, Ravi ; Gopinathannair, Rakesh</creator><creatorcontrib>Joglar, Jose A. ; Wan, Elaine Y. ; Chung, Mina K. ; Gutierrez, Alejandra ; Slaughter, Mark S. ; Bateson, Brian P. ; Loguidice, Michael ; Drazner, Mark ; Kistler, Peter M. ; Saour, Basil ; Poole, Jeanne E. ; Murtaza, Ghulam ; Turagam, Mohit K. ; Vader, Justin ; Lakkireddy, Dhanunjaya ; Birati, Edo Y. ; Dhingra, Ravi ; Gopinathannair, Rakesh</creatorcontrib><description>Orthotropic heart transplantation remains the most effective therapy for patients with end-stage heart failure, with a median survival of ≈13 years. Yet, a number of complications are observed after orthotropic heart transplantation, including atrial and ventricular arrhythmias. Several factors contribute to arrhythmias, such as autonomic denervation, effect of the surgical technique, acute and chronic rejection, and transplant vasculopathy among others. To minimize risk of future arrhythmias, the bicaval technique and minimizing ischemic time are current surgical standards. Sinus node dysfunction is the most common indication for early (within 30 days) pacemaker implantation, whereas atrioventricular block incidence increases as time from transplant increases. Atrial fibrillation can occur in the first few weeks following transplantation but is uncommon in the long term unless secondary to a precipitant such as acute rejection. The most common atrial arrhythmias are atrial flutters, which are mainly typical, but atypical circuits can be observed such as those that involve the remnant donor atrium in regions immediately adjacent to the atrioatrial anastomosis suture line. Choosing the appropriate pharmacological therapy requires careful consideration due to the potential interaction with immunosuppressive agents. Despite historical concerns, adenosine is effective and safe at reduced doses if administered under cardiac monitoring. Catheter ablation has emerged as an effective treatment strategy for symptomatic supraventricular tachycardias, including ablation of atypical flutter circuits. Cardiac allograft vasculopathy is an important risk factor for sudden cardiac death, yet the role of prophylactic implantable cardioverter-defibrillator implant for sudden death prevention is unclear. Current indications for implantable cardioverter-defibrillator implantation are as in the nontransplant population. A number of questions for future research are posed.</description><identifier>ISSN: 1941-3084</identifier><identifier>ISSN: 1941-3149</identifier><identifier>EISSN: 1941-3084</identifier><identifier>DOI: 10.1161/CIRCEP.120.007954</identifier><identifier>PMID: 33685207</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Action Potentials ; Animals ; Anti-Arrhythmia Agents - adverse effects ; Anti-Arrhythmia Agents - therapeutic use ; Arrhythmias, Cardiac - etiology ; Arrhythmias, Cardiac - mortality ; Arrhythmias, Cardiac - physiopathology ; Arrhythmias, Cardiac - therapy ; Catheter Ablation - adverse effects ; Catheter Ablation - mortality ; Defibrillators, Implantable ; Electric Countershock - adverse effects ; Electric Countershock - instrumentation ; Electric Countershock - mortality ; Heart Rate - drug effects ; Heart Transplantation - adverse effects ; Heart Transplantation - mortality ; Humans ; Risk Factors ; Treatment Outcome</subject><ispartof>Circulation. Arrhythmia and electrophysiology, 2021-03, Vol.14 (3), p.e007954-e007954</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3465-d77e5a783fefab569d52a4f8039c32a71a91fb311ed1ab1c25f1971bfd5e0c653</citedby><cites>FETCH-LOGICAL-c3465-d77e5a783fefab569d52a4f8039c32a71a91fb311ed1ab1c25f1971bfd5e0c653</cites><orcidid>0000-0002-5328-7282 ; 0000-0002-1492-2693 ; 0000-0003-4611-3687 ; 0000-0002-2022-6045 ; 0000-0002-8198-3437 ; 0000-0002-7933-7794 ; 0000-0002-7835-6045 ; 0000-0001-8183-8443 ; 0000-0002-8481-7389 ; 0000-0003-3054-4757 ; 0000-0001-6595-6204 ; 0000-0003-0110-3223 ; 0000-0002-3267-7601</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33685207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joglar, Jose A.</creatorcontrib><creatorcontrib>Wan, Elaine Y.</creatorcontrib><creatorcontrib>Chung, Mina K.</creatorcontrib><creatorcontrib>Gutierrez, Alejandra</creatorcontrib><creatorcontrib>Slaughter, Mark S.</creatorcontrib><creatorcontrib>Bateson, Brian P.</creatorcontrib><creatorcontrib>Loguidice, Michael</creatorcontrib><creatorcontrib>Drazner, Mark</creatorcontrib><creatorcontrib>Kistler, Peter M.</creatorcontrib><creatorcontrib>Saour, Basil</creatorcontrib><creatorcontrib>Poole, Jeanne E.</creatorcontrib><creatorcontrib>Murtaza, Ghulam</creatorcontrib><creatorcontrib>Turagam, Mohit K.</creatorcontrib><creatorcontrib>Vader, Justin</creatorcontrib><creatorcontrib>Lakkireddy, Dhanunjaya</creatorcontrib><creatorcontrib>Birati, Edo Y.</creatorcontrib><creatorcontrib>Dhingra, Ravi</creatorcontrib><creatorcontrib>Gopinathannair, Rakesh</creatorcontrib><title>Management of Arrhythmias After Heart Transplant: Current State and Considerations for Future Research</title><title>Circulation. Arrhythmia and electrophysiology</title><addtitle>Circ Arrhythm Electrophysiol</addtitle><description>Orthotropic heart transplantation remains the most effective therapy for patients with end-stage heart failure, with a median survival of ≈13 years. Yet, a number of complications are observed after orthotropic heart transplantation, including atrial and ventricular arrhythmias. Several factors contribute to arrhythmias, such as autonomic denervation, effect of the surgical technique, acute and chronic rejection, and transplant vasculopathy among others. To minimize risk of future arrhythmias, the bicaval technique and minimizing ischemic time are current surgical standards. Sinus node dysfunction is the most common indication for early (within 30 days) pacemaker implantation, whereas atrioventricular block incidence increases as time from transplant increases. Atrial fibrillation can occur in the first few weeks following transplantation but is uncommon in the long term unless secondary to a precipitant such as acute rejection. The most common atrial arrhythmias are atrial flutters, which are mainly typical, but atypical circuits can be observed such as those that involve the remnant donor atrium in regions immediately adjacent to the atrioatrial anastomosis suture line. Choosing the appropriate pharmacological therapy requires careful consideration due to the potential interaction with immunosuppressive agents. Despite historical concerns, adenosine is effective and safe at reduced doses if administered under cardiac monitoring. Catheter ablation has emerged as an effective treatment strategy for symptomatic supraventricular tachycardias, including ablation of atypical flutter circuits. Cardiac allograft vasculopathy is an important risk factor for sudden cardiac death, yet the role of prophylactic implantable cardioverter-defibrillator implant for sudden death prevention is unclear. Current indications for implantable cardioverter-defibrillator implantation are as in the nontransplant population. A number of questions for future research are posed.</description><subject>Action Potentials</subject><subject>Animals</subject><subject>Anti-Arrhythmia Agents - adverse effects</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Arrhythmias, Cardiac - etiology</subject><subject>Arrhythmias, Cardiac - mortality</subject><subject>Arrhythmias, Cardiac - physiopathology</subject><subject>Arrhythmias, Cardiac - therapy</subject><subject>Catheter Ablation - adverse effects</subject><subject>Catheter Ablation - mortality</subject><subject>Defibrillators, Implantable</subject><subject>Electric Countershock - adverse effects</subject><subject>Electric Countershock - instrumentation</subject><subject>Electric Countershock - mortality</subject><subject>Heart Rate - drug effects</subject><subject>Heart Transplantation - adverse effects</subject><subject>Heart Transplantation - mortality</subject><subject>Humans</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><issn>1941-3084</issn><issn>1941-3149</issn><issn>1941-3084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMtOwzAQRS0Eorw-gA3yD6TMxHEe7KqIl1QEgrKOJsmYFNKksh0h_p5UAcRidO_inlkcIc4R5ogxXub3z_n10xxDmAMkmY72xBFmEQYK0mj_X5-JY-feAWJMMT4UM6XiVIeQHAnzQB298YY7L3sjF9Y2X77ZrMnJhfFs5R2T9XJlqXPbljp_JfPB2t38xZNnSV0t875z65ot-fXYpOmtvBn8YFk-sxv5qjkVB4Zax2c_eSJeb65X-V2wfLy9zxfLoFJRrIM6SVhTkirDhkodZ7UOKTIpqKxSISVIGZpSIXKNVGIVaoNZgqWpNUMVa3UicPpb2d45y6bY2vWG7FeBUOycFZOzYnRWTM5G5mJitkO54fqP-JU0DqJp8Nm3oxL30Q6fbIuGqfVNAahUEmUqCCFEUAAQjIdafQN22ni4</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Joglar, Jose A.</creator><creator>Wan, Elaine Y.</creator><creator>Chung, Mina K.</creator><creator>Gutierrez, Alejandra</creator><creator>Slaughter, Mark S.</creator><creator>Bateson, Brian P.</creator><creator>Loguidice, Michael</creator><creator>Drazner, Mark</creator><creator>Kistler, Peter M.</creator><creator>Saour, Basil</creator><creator>Poole, Jeanne E.</creator><creator>Murtaza, Ghulam</creator><creator>Turagam, Mohit K.</creator><creator>Vader, Justin</creator><creator>Lakkireddy, Dhanunjaya</creator><creator>Birati, Edo Y.</creator><creator>Dhingra, Ravi</creator><creator>Gopinathannair, Rakesh</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-5328-7282</orcidid><orcidid>https://orcid.org/0000-0002-1492-2693</orcidid><orcidid>https://orcid.org/0000-0003-4611-3687</orcidid><orcidid>https://orcid.org/0000-0002-2022-6045</orcidid><orcidid>https://orcid.org/0000-0002-8198-3437</orcidid><orcidid>https://orcid.org/0000-0002-7933-7794</orcidid><orcidid>https://orcid.org/0000-0002-7835-6045</orcidid><orcidid>https://orcid.org/0000-0001-8183-8443</orcidid><orcidid>https://orcid.org/0000-0002-8481-7389</orcidid><orcidid>https://orcid.org/0000-0003-3054-4757</orcidid><orcidid>https://orcid.org/0000-0001-6595-6204</orcidid><orcidid>https://orcid.org/0000-0003-0110-3223</orcidid><orcidid>https://orcid.org/0000-0002-3267-7601</orcidid></search><sort><creationdate>20210301</creationdate><title>Management of Arrhythmias After Heart Transplant: Current State and Considerations for Future Research</title><author>Joglar, Jose A. ; Wan, Elaine Y. ; Chung, Mina K. ; Gutierrez, Alejandra ; Slaughter, Mark S. ; Bateson, Brian P. ; Loguidice, Michael ; Drazner, Mark ; Kistler, Peter M. ; Saour, Basil ; Poole, Jeanne E. ; Murtaza, Ghulam ; Turagam, Mohit K. ; Vader, Justin ; Lakkireddy, Dhanunjaya ; Birati, Edo Y. ; Dhingra, Ravi ; Gopinathannair, Rakesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3465-d77e5a783fefab569d52a4f8039c32a71a91fb311ed1ab1c25f1971bfd5e0c653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Action Potentials</topic><topic>Animals</topic><topic>Anti-Arrhythmia Agents - adverse effects</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Arrhythmias, Cardiac - etiology</topic><topic>Arrhythmias, Cardiac - mortality</topic><topic>Arrhythmias, Cardiac - physiopathology</topic><topic>Arrhythmias, Cardiac - therapy</topic><topic>Catheter Ablation - adverse effects</topic><topic>Catheter Ablation - mortality</topic><topic>Defibrillators, Implantable</topic><topic>Electric Countershock - adverse effects</topic><topic>Electric Countershock - instrumentation</topic><topic>Electric Countershock - mortality</topic><topic>Heart Rate - drug effects</topic><topic>Heart Transplantation - adverse effects</topic><topic>Heart Transplantation - mortality</topic><topic>Humans</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joglar, Jose A.</creatorcontrib><creatorcontrib>Wan, Elaine Y.</creatorcontrib><creatorcontrib>Chung, Mina K.</creatorcontrib><creatorcontrib>Gutierrez, Alejandra</creatorcontrib><creatorcontrib>Slaughter, Mark S.</creatorcontrib><creatorcontrib>Bateson, Brian P.</creatorcontrib><creatorcontrib>Loguidice, Michael</creatorcontrib><creatorcontrib>Drazner, Mark</creatorcontrib><creatorcontrib>Kistler, Peter M.</creatorcontrib><creatorcontrib>Saour, Basil</creatorcontrib><creatorcontrib>Poole, Jeanne E.</creatorcontrib><creatorcontrib>Murtaza, Ghulam</creatorcontrib><creatorcontrib>Turagam, Mohit K.</creatorcontrib><creatorcontrib>Vader, Justin</creatorcontrib><creatorcontrib>Lakkireddy, Dhanunjaya</creatorcontrib><creatorcontrib>Birati, Edo Y.</creatorcontrib><creatorcontrib>Dhingra, Ravi</creatorcontrib><creatorcontrib>Gopinathannair, Rakesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Circulation. Arrhythmia and electrophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joglar, Jose A.</au><au>Wan, Elaine Y.</au><au>Chung, Mina K.</au><au>Gutierrez, Alejandra</au><au>Slaughter, Mark S.</au><au>Bateson, Brian P.</au><au>Loguidice, Michael</au><au>Drazner, Mark</au><au>Kistler, Peter M.</au><au>Saour, Basil</au><au>Poole, Jeanne E.</au><au>Murtaza, Ghulam</au><au>Turagam, Mohit K.</au><au>Vader, Justin</au><au>Lakkireddy, Dhanunjaya</au><au>Birati, Edo Y.</au><au>Dhingra, Ravi</au><au>Gopinathannair, Rakesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Arrhythmias After Heart Transplant: Current State and Considerations for Future Research</atitle><jtitle>Circulation. Arrhythmia and electrophysiology</jtitle><addtitle>Circ Arrhythm Electrophysiol</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>14</volume><issue>3</issue><spage>e007954</spage><epage>e007954</epage><pages>e007954-e007954</pages><issn>1941-3084</issn><issn>1941-3149</issn><eissn>1941-3084</eissn><abstract>Orthotropic heart transplantation remains the most effective therapy for patients with end-stage heart failure, with a median survival of ≈13 years. Yet, a number of complications are observed after orthotropic heart transplantation, including atrial and ventricular arrhythmias. Several factors contribute to arrhythmias, such as autonomic denervation, effect of the surgical technique, acute and chronic rejection, and transplant vasculopathy among others. To minimize risk of future arrhythmias, the bicaval technique and minimizing ischemic time are current surgical standards. Sinus node dysfunction is the most common indication for early (within 30 days) pacemaker implantation, whereas atrioventricular block incidence increases as time from transplant increases. Atrial fibrillation can occur in the first few weeks following transplantation but is uncommon in the long term unless secondary to a precipitant such as acute rejection. The most common atrial arrhythmias are atrial flutters, which are mainly typical, but atypical circuits can be observed such as those that involve the remnant donor atrium in regions immediately adjacent to the atrioatrial anastomosis suture line. Choosing the appropriate pharmacological therapy requires careful consideration due to the potential interaction with immunosuppressive agents. Despite historical concerns, adenosine is effective and safe at reduced doses if administered under cardiac monitoring. Catheter ablation has emerged as an effective treatment strategy for symptomatic supraventricular tachycardias, including ablation of atypical flutter circuits. Cardiac allograft vasculopathy is an important risk factor for sudden cardiac death, yet the role of prophylactic implantable cardioverter-defibrillator implant for sudden death prevention is unclear. Current indications for implantable cardioverter-defibrillator implantation are as in the nontransplant population. A number of questions for future research are posed.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>33685207</pmid><doi>10.1161/CIRCEP.120.007954</doi><orcidid>https://orcid.org/0000-0002-5328-7282</orcidid><orcidid>https://orcid.org/0000-0002-1492-2693</orcidid><orcidid>https://orcid.org/0000-0003-4611-3687</orcidid><orcidid>https://orcid.org/0000-0002-2022-6045</orcidid><orcidid>https://orcid.org/0000-0002-8198-3437</orcidid><orcidid>https://orcid.org/0000-0002-7933-7794</orcidid><orcidid>https://orcid.org/0000-0002-7835-6045</orcidid><orcidid>https://orcid.org/0000-0001-8183-8443</orcidid><orcidid>https://orcid.org/0000-0002-8481-7389</orcidid><orcidid>https://orcid.org/0000-0003-3054-4757</orcidid><orcidid>https://orcid.org/0000-0001-6595-6204</orcidid><orcidid>https://orcid.org/0000-0003-0110-3223</orcidid><orcidid>https://orcid.org/0000-0002-3267-7601</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1941-3084
ispartof Circulation. Arrhythmia and electrophysiology, 2021-03, Vol.14 (3), p.e007954-e007954
issn 1941-3084
1941-3149
1941-3084
language eng
recordid cdi_crossref_primary_10_1161_CIRCEP_120_007954
source MEDLINE; American Heart Association; EZB-FREE-00999 freely available EZB journals
subjects Action Potentials
Animals
Anti-Arrhythmia Agents - adverse effects
Anti-Arrhythmia Agents - therapeutic use
Arrhythmias, Cardiac - etiology
Arrhythmias, Cardiac - mortality
Arrhythmias, Cardiac - physiopathology
Arrhythmias, Cardiac - therapy
Catheter Ablation - adverse effects
Catheter Ablation - mortality
Defibrillators, Implantable
Electric Countershock - adverse effects
Electric Countershock - instrumentation
Electric Countershock - mortality
Heart Rate - drug effects
Heart Transplantation - adverse effects
Heart Transplantation - mortality
Humans
Risk Factors
Treatment Outcome
title Management of Arrhythmias After Heart Transplant: Current State and Considerations for Future Research
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T20%3A36%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Arrhythmias%20After%20Heart%20Transplant:%20Current%20State%20and%20Considerations%20for%20Future%20Research&rft.jtitle=Circulation.%20Arrhythmia%20and%20electrophysiology&rft.au=Joglar,%20Jose%20A.&rft.date=2021-03-01&rft.volume=14&rft.issue=3&rft.spage=e007954&rft.epage=e007954&rft.pages=e007954-e007954&rft.issn=1941-3084&rft.eissn=1941-3084&rft_id=info:doi/10.1161/CIRCEP.120.007954&rft_dat=%3Cpubmed_cross%3E33685207%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33685207&rfr_iscdi=true